Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38Increases 2026 expected revenue growth to 15%-25%, exceeding the previous expectation of up to 10%
Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU®
CAMBRIDGE, MA / ACCESS Newswire / November 5,
WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 clinical results
CAMBRIDGE, MA / ACCESS Newswire / November 4, 2026 / Moderna, Inc. (NASDAQ:MRNA)
Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory multiple myeloma
CAMBRIDGE, MA / ACCESS Newswire / November 4, 2026 / Moderna, Inc. (NASDAQ:MRNA)
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are
AUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and
Investigation follows the October 22, 2026 disclosure regarding Moderna, Inc.; investors who lost money may have claims to recover their lossesInvestors who lost money on Moderna, Inc. ("Moderna" or the
Investigation comes after a October 22, 2026 report concerning Moderna, Inc.; shareholders who suffered losses may have claims to recover them
Investors who suffered losses on Moderna, Inc. ("Moderna" or the
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top
Investigation centers on the October 22, 2026 news about Moderna, Inc.; investors with losses may have potential claims to recover themModerna, Inc. ("Moderna" or the "Company") investors who lost money
Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected stage IIB-IV
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was
CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, November 6, 2026 to report its third
DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of
NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Moderna, Inc. (NASDAQ:MRNA) will become a component of the Nasdaq-100 Index® (NDX®) replacing Warner Bros. Discovery, Inc.
